John Andrew
Every year, more than 65,000 Americans receive a kidney cancer diagnosis, and about 13,000 people pass away from the condition. Kidney cancer is made up of several different cancer kinds, each of which has a unique histology, clinical course, and response to treatment, as well as being brought on by a separate gene. Kidney cancer is now understood to be a metabolic illness as a result of research into the thirteen genes that are known to cause kidney cancer. New areas of strong interest in the investigation of the underlying genetic basis of kidney cancer have been made possible by recent discoveries of chromatin remodeling/histone modifying genes, such as PBRM1 and SETD2. Ipilumumab, a CTLA4 inhibitor, and other novel immunotherapy strategies have opened up intriguing new avenues for clinical studies. The foundation for the creation of efficient treatments for this condition will hopefully be laid by a variety of fresh drugs that target VEGF receptor signaling, the mTOR pathway, and HIF2.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu